ROCK inhibitors synergize with the BCL2 inhibitor venetoclax for treatment of AML

被引：0
|
作者：
Golla, Upendarrao
Patel, Satyam
Tukaramrao, Diwakar B.
Hengst, Jeremy
Restrepo, Juliana
Amin, Shantu
Desai, Dhimant
Dovat, Sinisa
Claxton, David
Sharma, Arati
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2677
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax
    Sharpe, Chia
    Elgamal, Sara
    Fobare, Sydney
    Furby, Casie
    Long, Marissa
    Bryant, Kinsey
    Cheney, Carolyn
    Lerma, James R.
    Johnstone, Megan E.
    Orry, Andrew
    Lam, Polo Chun-Hung
    Abagyan, Ruben
    Kysil, Volodymyr
    Gukasyan, Hovhannes
    Mitkin, Oleg
    Karapetian, Ruben
    Ryakhovskiy, Alexey
    Bulanova, Elena
    Parchinsky, Vladislav
    Ivachtchenko, Alexandre
    Dokukina, Kate
    Pushechnikov, Alexei
    Savchuk, Nikolay
    Dukes, Iain
    Burd, Amy
    Hertlein, Erin K.
    Byrd, John C.
    BLOOD, 2023, 142
  • [22] Artemisinins Synergize with BCL2 Inhibitors By Reducing MCL1 Protein Levels in Leukemia Cells
    Moses, Blake S.
    Fox, Jennifer
    Chen, Xiaochun
    McCullough, Samantha
    Kirkpatrick, Allison
    Kumar, Kalyani
    Tyner, Jeffrey W.
    Posner, Gary H.
    Civin, Curt I.
    BLOOD, 2017, 130
  • [23] BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
    Gupta, Vikas A.
    Ackley, James
    Kaufman, Jonathan L.
    Boise, Lawrence H.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2021, 11 : 11 - 24
  • [24] Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax
    Karjalainen, Riikka
    Liu, Minxia
    Kumar, Ashwini
    Parsons, Alun
    Kontro, Mika
    Porkka, Kimmo
    Heckman, Caroline A.
    BLOOD, 2017, 130
  • [25] Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Roberts, Andrew W.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Puvvada, Soham D.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Brown, Jennifer R.
    Gressick, Lori
    Wong, Shekman
    Dunbar, Martin
    Zhu, Ming
    Desai, Monali B.
    Cerri, Elisa
    Enschede, Sari Heitner
    Humerickhouse, Rod A.
    Wierda, William G.
    Seymour, John F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04): : 311 - 322
  • [26] Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
    Katharina T. Prochazka
    Barbara Uhl
    memo - Magazine of European Medical Oncology, 2022, 15 : 45 - 48
  • [27] Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax
    Lew, Thomas E.
    Anderson, Mary Ann
    Tam, Constantine S.
    Huang, David C. S.
    Juneja, Surender
    Westerman, David A.
    Seymour, John F.
    Roberts, Andrew W.
    BLOOD, 2016, 128 (22)
  • [28] Bcl2 inhibitor venetoclax +/- Anti-CD20: what do deep remissions mean?
    Prochazka, Katharina T.
    Uhl, Barbara
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (01) : 45 - 48
  • [29] A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)
    Ando, Hidenori
    Murakami, Yuta
    Eshima, Kiyoshi
    Ishida, Tatsuhiro
    CANCER REPORTS, 2022, 5 (03)
  • [30] Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax
    Satta, Toshihisa
    Li, Lin
    Chalasani, Sri Lakshmi
    Hu, Xiaoyan
    Nkwocha, Jewel
    Sharma, Kanika
    Kmieciak, Maciej
    Rahmani, Mohamed
    Zhou, Liang
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2023, 29 (07) : 1332 - 1343
12345